In a filing, Athira Pharma Inc revealed its CHIEF SCIENTIFIC OFFICER CHURCH KEVIN unloaded Company’s shares for reported $2502.0 on Jul 01 ’25. In the deal valued at $0.29 per share,8,526 shares were sold. As a result of this transaction, CHURCH KEVIN now holds 168,901 shares worth roughly $55737.33.
Then, Litton Mark James sold 25,123 shares, generating $7,374 in total proceeds. Upon selling the shares at $0.29, the President and CEO now owns 325,802 shares.
Before that, San Martin Javier sold 10,842 shares. Athira Pharma Inc shares valued at $3,182 were divested by the CHIEF MEDICAL OFFICER at a price of $0.29 per share. As a result of the transaction, San Martin Javier now holds 71,665 shares, worth roughly $23649.45.
Mizuho downgraded its Athira Pharma Inc [ATHA] rating to a Neutral from a an Outperform in a research note published on September 19, 2024; the price target was decreased to $0.50 from $5. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who decreased its forecast for the stock in early September from “a Buy” to “a Neutral”. JMP Securities also remained covering ATHA and has decreased its forecast on September 04, 2024 with a “Mkt perform” recommendation from previously “Mkt outperform” rating. BTIG Research revised its rating on September 04, 2024. It rated ATHA as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ATHA
On Monday, Athira Pharma Inc [NASDAQ:ATHA] saw its stock fall -2.91% to $0.33. Over the last five days, the stock has gained 11.90%. Athira Pharma Inc shares have fallen nearly -86.90% since the year began. Nevertheless, the stocks have fallen -43.74% over the past one year. While a 52-week high of $3.67 was reached on 01/08/25, a 52-week low of $0.22 was recorded on 04/08/25.
Levels Of Support And Resistance For ATHA Stock
The 24-hour chart illustrates a support level at 0.3198, which if violated will result in even more drops to 0.3094. On the upside, there is a resistance level at 0.3508. A further resistance level may holdings at 0.3714.
How much short interest is there in Athira Pharma Inc?
A steep rise in short interest was recorded in Athira Pharma Inc stocks on 2025-06-13, growing by 0.73 million shares to a total of 1.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 0.75 million shares. There was a rise of 49.48%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 19, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $22 price target.
